Targeting specific protein interactions to improve cancer treatment
Selective disruption of histone deacetylase complexes using protein interaction modulators
This study is exploring new ways to treat cancer by targeting specific proteins in a way that could lead to more effective and safer therapies, so patients might get treatments that work better for them with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11010819 on NIH RePORTER |
What this research studies
This research focuses on developing new cancer therapies by targeting specific protein interactions within histone deacetylase (HDAC) complexes. Unlike traditional HDAC inhibitors that affect a wide range of genes, this approach aims to selectively disrupt only certain HDAC subcomplexes, potentially leading to more effective and safer treatments. By narrowing the impact on the transcriptome, the goal is to enhance anti-tumor effects while minimizing side effects. Patients may benefit from more personalized and effective cancer therapies as a result of this innovative strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of blood cancers who have not responded well to existing treatments.
Not a fit: Patients with solid tumors or those who do not have blood cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more targeted and effective cancer treatments with fewer side effects.
How similar studies have performed: Other research has shown promise in targeting specific protein interactions for cancer treatment, suggesting that this approach could be a viable alternative to traditional methods.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Vidal, Marc — Dana-Farber Cancer Inst
- Study coordinator: Vidal, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.